The First Affiliated Hospital of Xi'an Jiaotong University
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China22 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery | Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, cardiovascular disorder, ischemia reperfusion injury, vascular disorder | Recruiting | Not applicable | 2026-09-16 | NCT07383909 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Not applicable | 2026-08-19 | NCT07773051 | |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT07327229 | |
| SMP-656 for HER2-Positive Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-07-24 | NCT07726342 | |
| Evaluation of NWRD09 for HPV-16 Related Cervical HSIL | Morphological and Microscopic Findings, Pathological Conditions, Signs and Symptoms, Squamous Intraepithelial Lesions | Not yet recruiting | Phase 2 | 2026-07-17 | NCT07712692 | |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04849728 | |
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-06-17 | NCT07164170 | |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-04-13 | NCT06564324 | |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-01 | NCT03315364 | |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-03-13 | NCT06008288 | |
| IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors | PDAC; Solid Tumor Cancer | Recruiting | Phase 1 / Phase 2 | 2026-02-27 | NCT07441174 | |
| ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-01-08 | NCT07327034 | |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-12-23 | NCT06459973 | |
| SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Solid Tumor | Active, not recruiting | Phase 2 | 2025-10-14 | NCT05642780 | |
| A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC | non-small cell lung carcinoma | Not yet recruiting | Phase 2 | 2025-07-25 | NCT07086326 | |
| Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Phase 2 | 2025-03-20 | NCT06885840 | |
| Long-term Efficacy and Safety Study of GV-971 | Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 4 | 2024-11-15 | NCT05181475 | |
| The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). | Type1 Diabetes Mellitus | Not yet recruiting | Not stated | 2024-09-23 | NCT06606509 | |
| HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma, uterine disorder | Recruiting | Phase 2 | 2024-08-29 | NCT06014190 | |
| ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2024-08-20 | NCT06007729 |